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ABSTRACT
In eukaryotic cells the CDC7/DBF4 kinase, also
known as DBF4-dependent kinase (DDK), is required
for the firing of DNA replication origins. CDC7 is
also involved in replication stress responses and
its depletion sensitises cells to drugs that affect
fork progression, including Topoisomerase 2 poi-
sons. Although CDC7 is an important regulator of
cell division, relatively few substrates and bona-fide
CDC7 phosphorylation sites have been identified to
date in human cells. In this study, we have gen-
erated an active recombinant CDC7/DBF4 kinase
that can utilize bulky ATP analogues. By perform-
ing in vitro kinase assays using benzyl-thio-ATP,
we have identified TOP2A as a primary CDC7 sub-
strate in nuclear extracts, and serine 1213 and ser-
ine 1525 as in vitro phosphorylation sites. We show
that CDC7/DBF4 and TOP2A interact in cells, that
this interaction mainly occurs early in S-phase, and
that it is compromised after treatment with CDC7
inhibitors. We further provide evidence that human
DBF4 localises at centromeres, to which TOP2A is
progressively recruited during S-phase. Importantly,
we found that CDC7/DBF4 down-regulation, as well
S1213A/S1525A TOP2A mutations can advance the
timing of centromeric TOP2A recruitment in S-phase.
Our results indicate that TOP2A is a novel DDK tar-
get and have important implications for centromere
biology.
INTRODUCTION
In order to divide, cells must completely and accurately
replicate their DNA once every cell cycle. Incomplete or
over-replication can lead to cell death or genomic instabil-
ity, which is a major contributing factor in the development
of cancer (1,2). As such, DNA replication is a tightly regu-
lated andmonitored process (reviewed in (3,4)). TheDBF4-
dependent kinase (DDK), which is a complex formed by the
CDC7 catalytic subunit bound to either DBF4 or DBF4B
(5,6) is involved in multiple aspects of the regulation of
DNA replication. It is required for the firing of replica-
tion origins by phosphorylating multiple subunits of the
MCM2-7 helicase complex (7–9). In addition, CDC7 ki-
nase has important roles in the replication stress response
and chromatin function. For instance, in human cells CDC7
phosphorylation of the mediator protein CLASPIN is im-
portant for full activation of CHK1 by ATR and for main-
taining cell viability in the presence of drugs that affect
replication fork progression (10–12,13). Also, CDC7 phos-
phorylation of RAD18 is required for the efficient recruit-
ment of the translesion synthesis (TLS) polymerase Pol to
stalled forks (14,15). In human cells, CDC7 kinase has also
been shown to affect the function of the p150 Chromatin
Assembly Factor 1 (CAF1) subunit (16), while in yeast it
participates in the control of core histone levels (17), con-
tributes to centromeric heterochromatin function (18), and
directly phosphorylates HistoneH3 at Ser45 during replica-
tion (19). Importantly, several laboratories have elucidated
the role of CDC7 kinase in controlling the formation of
DNA double strand breaks during meiotic DNA replica-
tion to promote meiotic recombination (20–25).
In recent years, a chemical genetics approach has been de-
veloped that provides a novel tool for inhibiting a specific ki-
nase. The target kinase is mutated at a specific residue in the
ATP binding pocket, termed a ‘gatekeeper’ residue, and this
mutation enlarges the binding site sufficiently to allow en-
try and binding of novel small-molecule inhibitors, namely
bulky pyrazolo pyrimidine compounds (PP1s) and novel
staurosporine derivatives. Binding of these compounds can
inhibit the engineered kinase but they are too bulky to en-
ter the ATP pocket of other cellular kinases and are there-
fore unable to inhibit them (26,27). This approach has been
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widely used in a variety of organisms from budding yeast
to cultured human cells and transgenic mice with the spe-
cific goal of studying the function of a given kinase (28,29).
However, the identification of direct substrates and phos-
phorylation sites is still a challenging task. A recent im-
portant advance in this kinase chemical genetics approach
was the finding that the engineered kinase can now ac-
cept and utilize an unnatural and bulky ATP analogue (N6-
(benzyl)ATP). These analogues are very poor substrates
for wild-type kinases, thus only the analogue-sensitive ki-
nase (AS-kinase) can use the bulky ATP analogue. Fur-
ther modification of this analogue into N6-(benzyl)ATP- -
S (benzyl-thio-ATP) allows the transfer of a thio-phosphate
reactive group as a distinctive molecular tag by the AS-
kinase onto the substrate protein. Therefore, after an in
vitro kinase reaction and further derivatization of these re-
active groups with p-nitrobenzylmesylate (PNBM), labeled
proteins that are direct substrates of the AS-kinase can be
detected by western blotting (30). Furthermore, peptides
containing this unique thio-phosphate modification can be
specifically captured from digests of labeled protein mix-
tures; mass spectrometry is then used to reveal the identity
of the corresponding protein species and the location of the
phosphorylation site(s) (28,31–33).
In order to obtain further insights into possible sub-
strates and roles of human DDK in the mitotic cell cycle,
we have used the above-described approach and identified
Topoisomerase 2 alpha (TOP2A) as a prime in vitro sub-
strate of the kinase. Topoisomerase 2 (TOP2) enzymes re-
solve DNA catenates that form during DNA replication
by catalysing the transient breakage and religation of du-
plex DNA, while allowing the passage of a second duplex
through the gap (34,35). Of the two isoforms present in hu-
mans, only the alpha isoform,TOP2A, is essential for prolif-
eration of cultured cells (36). Although reportedly dispens-
able for DNA replication, TOP2A is essential for proper
chromosome condensation and sister chromatid separation,
as TOP2A-deficient cells exhibit an increased number of
amorphous and severely entangled chromosomes (36,37).
TOP2A also plays an important role in resolving ultra-
fine anaphase DNA bridges arising from centromeric loci
(38,39).
We have previously reported that treatment with etopo-
side, a TOP2 poison that prevents the religation step of
the TOP2 catalytic cycle, thus stabilizing an intermediate
TOP2-DNA covalent complex (40,41), inducedmore exten-
sive cell death when cells were also depleted of CDC7 (10).
The increased sensitivity to etoposide may be due to the
roles of CDC7 in the general response to replication stress,
or could perhaps reflect a functional interaction between
CDC7 kinase and TOP2. In this study, we explored the lat-
ter hypothesis and we found that CDC7/DBF4 physically
and functionally interacts with TOP2A in human cells.
MATERIALS AND METHODS
Cell culture and chemicals
Flp-In T-REx 293 cells (Invitrogen) and U2OS (obtained
from the Centre for Chromosome Biology, NUI Galway,
and validated by STR analysis), were grown in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine
serum and maintained at 37◦C with 5% CO2 in a humidi-
fied atmosphere.Nocodazole (Sigma)was used at 1M,mi-
mosine (Sigma) at 1 mM, PHA-767491 (Tocris) and XL413
(synthesized in house (11)) at 10 M, DMSO was used
as control. Plasmids and siRNA transfections were per-
formed using jetPEI and jetPRIME (Polyplus Transfec-
tion) respectively according to manufacturer’s instructions.
siRNAs for CDC7 and DBF4 were obtained from Dhar-
macon. Control non-targeting siRNA AGUACUGCU-
UACGAUACGG from Ambion.
DNA plasmids
EGFP-DBF4 expression construct was obtained by cloning
DBF4 coding sequence into vector pIC111 (42). N-terminal
tagged (S-Tag-2xFLAG) TOP2A was obtained from Luo
(43), and the coding sequence was PCR amplified and
cloned into vector pcDNA3.1. The plasmid was subject to
site-directed mutagenesis (Agilent, Quickchange II XL) to
obtain constructs expressing S-Tag-2xFLAG-TOP2A WT,
S1213A/S1525A and S1213D/S1525D mutants. All con-
structs were verified by sequencing.
Recombinant protein expression and purification
All recombinant proteins were expressed in Escherichia coli
and purified using GSTrap FF or HisTrap FF columns (GE
Healthcare) according tomanufacturer’s instructions.GST-
tagged recombinant human CDC7–DBF4[197–333] com-
plex and MCM2[Nterm] were eluted using PreScission pro-
tease to remove the GST-tag. The M118A, M134A and
M118/M134A CDC7 was obtain by site directed mutagen-
esis of pGEX-CDC7/DBF4MC previously described (11).
Preparation of nuclear extract
Cells were resuspended in hypotonic buffer (10mMHEPES
pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM TCEP and
protease inhibitors) and allowed to swell on ice for 20 min.
An equal volume of lysis buffer (10 mM HEPES pH 7.5,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM TCEP, 1.0% NP40
and protease inhibitors) was added to the cells and mixed
by brief vortex. Nuclei were pelleted by centrifugation (450
× g, 5 min, 4◦C) and lysed (50mMHEPES pH 7.5, 150mM
NaCl, 1.5 mMMgCl2, 0.5 mM TCEP, 0.05% (v/v) Tween-
20, protease inhibitors, and 0.25 U/l Benzonase (Sigma)
to digest chromatin).
In vitro thio-phosphorylation
Twenty microgram of nuclear extract was incubated with
200 ng of AS-CDC7/DBF4MC in the presence of ATP or
50 M N6-(benzyl)ATP- -S, 1 mM GTP in kinase buffer
(50 mM HEPES pH 7.5, 10 mM MgCl2, 0.5 mM TCEP
and protease inhibitor) for 30 min at 30◦C in a final vol-
ume of 20l. The reactionwas terminated by adding EDTA
to 20 mM. The mixture was alkylated with 2.5 mM p-
nitrobenzylmesylate (PNBM) for 1.5 h at room tempera-
ture, heated in Laemmli buffer, and analyzed by western
blot with anti-thiophosphate ester antibody (30).
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Covalent capture of thio-phosphorylated AS-CDC7 sub-
strates
Eight milligrams of nuclear extract prepared from XL413-
treated cells was incubated with purified recombinant AS-
CDC7/DBF4MC to 1% by mass of total protein, 50 M
N6-(benzyl)ATP- -S, and 1.5 mMGTP in kinase buffer for
30 min at 30◦C. The reactions were stopped by the addi-
tion of 20 mM EDTA. The proteins were precipitated with
methanol/chloroform and digested with trypsin. The de-
salted peptides were added to iodoacetylagarose beads (Sul-
foLink gel, Pierce) in buffer (25 mM HEPES pH 7.0, BSA
25 g/ml, TCEP 2 mM, 50% acetonitrile). The beads were
incubated overnight in the dark with rotation, washed once
with water, followed by 5MNaCl, 50% acetonitrile, and 5%
formic acid in water. The beads were then incubated in 1 ml
10mMDTTprior to elutionwith 200l of freshly prepared
2 mg/ml Oxone. The phosphopeptides were desalted and
enriched by PierceTM Magnetic Titanium Dioxide Phos-
phopeptide Enrichment Kit (ThermoFisher Scientific). The
recovered peptides were analyzed by LC–MS/MS.
Liquid chromatography–tandemMS (LC–MS/MS) analysis
Five microliters of desalted solution was injected in a cap-
illary chromatographic system (Agilent 1100 Series, Agi-
lent Technologies, Waldbronn, Germany). Peptide separa-
tions occurred on a RP homemade 15 cm reverse-phase
spraying fused silica capillary column (75 m i.d. × 15
cm), packed with 3 m ReproSil C18 AQ (Dr. Maisch
GmbH, Germany). A gradient of eluents A (5% acetoni-
trile, 0.1% formic acid) and B (acetonitrile, 0.1% formic
acid) was used to achieve separation, from 8% B to 80%
B in 48 min, at 0.3 l/min flow rate. The LC system was
connected to a Fourier transformed-LTQ Ultra mass spec-
trometer (FT-LTQ Ultra, Thermo Electron, San Jose, CA,
USA) equipped with a nanoelectrospray ion source (Prox-
eon Biosystems, Odense, Denmark). Survey MS scans were
acquired in the FT from m/z 350–1650 with 100 000 res-
olution. The six most intense doubly and triply charged
ions were automatically selected for fragmentation. Target
ions already selected for the MS/MS were dynamically ex-
cluded for 30s; the data-dependent neutral loss algorithm
was enabled for each MS/MS spectra to trigger a MS3
scan (44). DATABASE SEARCHING–Raw MS files were
converted using Raw2msm software (.msm files); MS2 and
MS3 peak lists were analyzed using (Matrix Science, Lon-
don, UK; version 2.3.02). Mascot was set up to search
theUniProt CP Human 20150401 database (unknown ver-
sion, 90 411 entries) with trypsin as digestion enzyme. Mas-
cot was searched with a fragment ionmass tolerance of 0.50
Da and a parent ion tolerance of 10 PPM. Deamidation of
asparagine and glutamine, oxidation and dioxidation ofme-
thionine, acetylation of the N-terminus, carbamidomethyl
of cysteine, phosphorylation of serine, threonine and ty-
rosine were specified in Mascot as variable modifications.
Criteria for protein identification––Scaffold (version Scaf-
fold 4.4.3, Proteome Software Inc., Portland, OR, USA)
was used to validate MS/MS based peptide and protein
identifications. Peptide identifications were accepted if they
could be established at >95.0% probability by the Peptide
Prophet algorithm (45) with Scaffold delta-mass correction.
Protein identifications were accepted if they could be estab-
lished at greater than 99,0% probability and contained at
least two identified peptides. Protein probabilities were as-
signed by the Protein Prophet algorithm (46). Proteins that
contained similar peptides and could not be differentiated
based onMS/MS analysis alone were grouped to satisfy the
principles of parsimony.
Immunoprecipitations
Nuclei were isolated as described, and chromatin-bound
proteins were released by Benzonase treatment in IP buffer
(50 mM Tris pH 7.6, 150 mM NaCl, 2 mM MgCl2, 1 mM
EDTA, 1% Triton X-100). IgG or anti-TOP2A antibody
were prebound to protein A resin (GeneSpin) and equal
amounts of precleared nuclear extract were immunoprecipi-
tated for 2 h with rotation at 4◦C. Following washes with IP
buffer, proteins were recovered in 1× Laemmli buffer and
analysed by SDS-PAGE and western blotting.
Antibodies and western blotting
Primary antibodies included: anti-CDC7 (MBL
International), anti-TOP2A (Millipore), anti-
NWSHPQFEK/Strep-tag (GenScript), anti-centromere
antibodies (ACA) (Antibodies Incorporated), anti-MCM2
(AbD Serotec), anti-pSer40/41 MCM2 described in (7),
-actin (Sigma), anti-RPB1 (Santa-Cruz Biotechnol-
ogy), anti--tubulin (Santa-Cruz Biotechnology), and
anti-thiophosphate ester (Abcam). Equal amounts of cell
extract were resolved on 7.5% or 10% gels for standard
SDS-PAGE, or 5% gels with 5 M Phos-tag acrylamide
(Wako Pure Chemical Industries) and 10 M MnCl2
for phosphorylation-dependent mobility shift detection,
and subject to western blot analysis. IRDye R© secondary
antibodies for protein detection using the Odyssey infrared
imaging system were used (Li-COR Biosciences). For
dephosphorylation assays, 20 g of extracts were incubated
with 20 U of Lambda Phosphatase (Sigma) for 30 min
before SDS-PAGE.
Immunofluorescence microscopy
Cells were grown on glass coverslips and treated as de-
scribed in the text. Soluble proteins were pre-extracted on
ice for 5 min with ice-cold HPEM buffer (30 mM HEPES,
65 mM PIPES, 100 mM NaCl, 10 mM EGTA, 2 mM
MgCl2, 0.5% Triton X-100) and fixed with 4% PFA for
10 min at room temperature. Coverslips were incubated
in blocking buffer (3% bovine serum albumin in PBS) for
30 min, followed by primary antibodies diluted in block-
ing buffer for 1 h. For EdU labeling, coverslips were then
incubated in Click reaction solution (10 M azide-fluor
545, 10 mM sodium-L-ascorbate, 2 mM CuSO4) for 30
min and washed. Finally, coverslips were incubated with
the appropriate Alexa Fluor secondary antibodies (Ther-
moFisher Scientific), and DNA was counterstained with
4′,6-diamidino-2-phenylindole (DAPI). Images were cap-
tured using a DeltaVision Core system (Applied Preci-
sion) controlling an interline charge-coupled device camera
(Coolsnap HQ2; Roper Technologies) mounted on an in-
vertedmicroscope (IX-71; Olympus). Images were collected
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at 2× binning using a 60× or 100× oil objective. Z-series
were collected using 0.2 m intervals. Images were decon-
volved using SoftWoRx (Applied Precision).
Flow cytometry
For the analysis of DNA content, cells were fixed with 70%
ethanol/PBS, centrifuged, resuspended in PBS containing
RNase A (2 g/ml) and propidium iodide (5 g/ml), and
incubated for 30 min. Samples were analyzed using a BD
FACS CantoA (BD Bioscences).
Chromatin immunoprecipitation (ChIP)
Cells were washed once with cold PBS, counted, and re-
suspended in PBS at room-temperature. Cross-linking was
performed with 1.5 mM ethylene glycol bis (succinimidyl
succinate) (EGS) from Thermo Fisher Scientific and 1%
PFA for a total of 35 and 10 min, respectively. Fixation
was quenched with 50 mM glycine. Nuclei were isolated
by sequential incubation in Buffer A (100 mM Tris pH 8,
10 mM DTT), Buffer B (10 mM HEPES pH 7.5, 0.25%
Triton X-100) and buffer C (10 mM HEPES pH 7.5, 200
mM NaCl). Chromatin was digested with MNase in diges-
tion buffer (50 mM Tris pH 8, 5 mM CaCl2), to mostly
mono and dinucleosomes with some trinucleosomes, and
briefly sonicated to lyse nuclear membranes. Insoluble ma-
terial was removed by centrifugation (16 000 × g, 10 min).
Supernatant was diluted with ChIP IP buffer (20 mM Tris
pH 8, 150 mM NaCl, 2.5 mM MgCl2, 0.5% Triton X-100,
0.1% Nonidet P-40) and incubated for 16 h with primary
antibodies. Antibody complexes were recovered with Pro-
tein A/G beads (Thermo Fisher Scientific), and washed ex-
tensively with IP buffer, LiCl wash buffer (10 mM Tris pH
8, 1 mM EDTA, 250 mM LiCl2, 1% Nonidet P-40, 1%
sodium deoxycholate) and TE buffer. Samples were eluted
with elution buffer (0.1 M NaHCO3, 1% SDS) for 45 min
at 65◦C with constant agitation. Cross-links were reversed
by incubation at 65◦C for 18 h. Recovered DNA was anal-
ysed on a StepOnePlus Real-Time PCR System (Applied
Biosystems). Primers were selected to amplify a 201 bp
centromeric sequence specific to chromosome 1 (Fwd: GG
CCTATGGCAGCAGAGGATATAACTGCC, Rev: GT
GAGTTTTCTCCCGTATCCAACGAAATCC) (47), and
a 165 bp non-centromeric sequence at the GAPDH pro-
moter (sequences provided by Thermo Fisher Scientific;
Fwd: TACTAGCGGTTTTACGGGCG, Rev: TCGAAC
AGGAGGAGCAGAGAGCGA).
Statistics
Graphs and statistical analyses were performed using
GraphPad Prism software.
RESULTS
Generation of an engineered CDC7 kinase and identification
of TOP2A as an in vitro substrate
Based on sequence alignments and structural information,
M118 and M134 appear to constrict the CDC7 ATP-
binding pocket and could be considered the putative gate-
Figure 1. Covalent capture of thio-phosphorylated peptides by AS-
CDC7. (A) In vitro kinase assay with recombinant WT or M118A,
M134A and M118A/M1134A CDC7/DBF4, recombinant MCM2 and
N6-(benzyl)ATP- -S. Thio-phosphorylated MCM2 and CDC7 proteins
are detected by western blotting. Ponceau-stained membrane shows equal
amount of MCM2 substrate in reactions. (B) Western blot detection
of thio-phosphorylated proteins after kinase reaction with nuclear ex-
tracts and N6-(benzyl)ATP in the presence or absence of AS-CDC7. (C)
List of proteins and peptides identified after covalent capture of thio-
phosphorylated peptides. The sites of modification are indicated in red.
keeper residues of the kinase (48,49). By site directed muta-
genesis, we changed the codons for M118 and M134 either
individually or in combination, in order to generate three
different potential analogue sensitive (AS) alleles of CDC7,
namely M118A, M134A and the double M118A/M134A.
The wild type (WT) and the three potential AS-CDC7 pro-
teins were then expressed in E. coli as GST-fusions together
with a polypeptide corresponding to amino acids 197 to 334
of the DBF4 protein, which is sufficient to bind to and acti-
vate the kinase (11). Proteins were purified on GST affinity
beads, GST-tags were cleaved, and their capability to trans-
fer thio-phosphate groups fromN6-(benzyl)ATP- -S to the
MCM2 protein was tested in in vitro kinase reactions. We
found that all the three putative AS-CDC7 proteins, but not
WT CDC7 could thio-phosphorylate MCM2 and observed
that M118A/M134A double mutant was the most efficient
in catalyzing the reaction (Figure 1A). Thus, for all the sub-
sequent experiments, we used the M118A/M134A double
mutant as the AS-CDC7 protein kinase.
In order to maximise the chances of identifying relevant
cellular CDC7 substrates, we prepared large quantities of
benzonase-treated nuclear extracts from HEK293 cells that
had been challenged with the CDC7 inhibitor XL413 (50),
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thus leading to the in vivo dephosphorylation of relevant
substrates by counteracting protein phosphatases and to the
solubilization of chromatin-bound proteins. After in vitro
kinase reactions with AS-CDC7 and N6-(benzyl)ATP- -S,
we could detect several specific thio-phosphorylated bands
by western blotting, with the most intense one migrating
similarly to the recombinant AS-CDC7 kinase (Figure 1B
and data not shown).
Proteins were then digested, thio-phosphorylated pep-
tides captured on iodoacetylagarose beads, eluted as phos-
phopeptides by oxidation with Oxone, and identified by
mass spectrometry. With this methodology, we identi-
fied several peptides derived from CDC7 and DBF4 pro-
teins, indicating that the kinase undergoes extensive auto-
phosphorylation.We also identified several phosphorylated
peptides from cellular proteins, and most notably peptides
derived from TOP2A phosphorylated at serine 1213 and
serine 1525 (Figure 1C and Supplementary Figure S1).
These observations, together with the previous findings
that CDC7 and TOP2 inhibitors synergise in causing cell
death of cancer cells (10), lead us to postulate that the two
proteins could functionally interact in cells.
CDC7/DBF4 and TOP2A interact in vivo
To begin assessing if active DDK physically interacts with
TOP2 in cell extracts, we devised new tools to purify DBF4
and its associated proteins. Specifically, we used the Flp-
In T-REx 293 system to generate a stable cell line with
a single-site integration of DBF4 fused to tandem FLAG
andStrep tags on the carboxyl-terminus (T-REx–DBF4). In
this cell line, tagged DBF4 expression is normally repressed
by upstream TetO2 sequences bound by the Tet repres-
sor, but its expression is induced by the addition of doxy-
cycline. A control cell line with integration of the empty
vector (EV) was generated in parallel. We found that ex-
pression of tagged DBF4 did not obviously affect viability
or cell cycle progression (Supplementary Figure S2A and
S2B). Having assessed that TOP2A can only be solubilized
by chromatin digestion when nuclear extracts are prepared
at 150 mM NaCl, and knowing that CDC7 kinase under
the same condition is also partially chromatin associated
(Figure 2A and (10)) we then performed immunoprecipi-
tations (IP) from benzonase-treated extracts prepared from
both T-REx–DBF4 and T-REx–EV cells with anti-FLAG
antibodies. After western blotting we observed that tagged
DBF4 not only interacts with endogenous CDC7, but also
co-immunoprecipitates with TOP2A (Figure 2B).
Three short conserved motifs, named motifs N, M and
C can be recognized in the DBF4 protein (6,51,52). The
N terminal motif contains a BRCA1 C-terminal (BRCT)
domain predicted to be involved in protein-protein inter-
actions, while motifs M and C bind directly to the CDC7
subunit and activate the kinase (5,49). Human DBF4 ad-
ditionally contains a large tail region, representing almost
half of the protein, which contains no recognisable mo-
tifs. To map the DBF4 domains required for its interaction
with TOP2A, we cloned several fragments of DBF4 open
reading frames containing deletions of their N (residues 1–
209), MC (210–350), or Tail (351–674) domains (Figure
2C). Flp-In T-REx cell lines were then generated as be-
Figure 2. CDC7/DBF4 interacts with TOP2A. (A) Proteins extracted
from nuclei with or without Benzonase were analysed by western blot-
ting with the indicated antibodies. (B) Immunoprecipitations (IP) with
anti-FLAGantibodieswere performed fromT-REx-EVandT-REx-DBF4
cells. (C) Schematic of DBF4 deletion mutant alleles used to generate Flp-
In T-REx 293 conditionally expressing cell lines. (D) Detection of DBF4
fragments by western blotting in nuclear extracts prepared from Flp-In
T-REx 293 cells upon addition of doxycycline. Asterisks indicate cross-
reactive bands. (E) Endogenous TOP2Awas immunoprecipitated from nu-
clear extracts and immunoprecpitated material was analysed by western
blotting.
fore, and the expression of the taggedDBF4 fragments were
confirmed by western blotting although to different levels
with the C-terminal tail expressing the least (Figure 2D).
We then immunoprecipitated endogenous TOP2A from ex-
tracts prepared from these cell lines, and the co-purification
of each of the DBF4 fragments was determined by west-
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Figure 3. CDC7/DBF4 interacts with TOP2A predominantly in early S-
phase. (A) T-REx-DBF4 cells were treated with mimosine or nocodazole
for 19 h and DNA content analysed by Flow Cytometry. (B) Extracts were
prepared from asynchronously growing, mimosine and nocodazole treated
cells as in panel A and TOP2A was immunopreciptiated with specific an-
tibodies. As control, unrelated mouse IgG was used. Immunoprecipitated
proteins were then analysed by western blotting. (C) DNA content of cells
treated with mimosine for 15 h and released into fresh media. Samples
were collected at the indicated time-points. (D) TOP2A immunoprecipi-
tates from extracts of cells released from mimosine block as in panel C.
ern blotting. As expected, full-length DBF4 (FL) was co-
immunoprecipitated with TOP2A (Figure 2E, lane 1). Of
the fragments, only the DBF4 MCT (210–674) and NMC
(1–350) were co-immunoprecipitated with TOP2A (Figure
2E, lanes 3 and 4), indicating that the N domain is dis-
pensable and that the MC domains are required. While
we could not detect a direct binding between TOP2A and
the C-terminal tail of DBF4 in these experiments, we ob-
served that the binding of theMCT fragment wasmore pro-
nounced compared to the NMC, strongly suggesting that
the tail contributes to this protein-protein interaction. This
could be achieved either by stabilizing the overall structure
of the CDC7 complex or by providing a second independent
binding site.
CDC7/DBF4-TOP2A interaction occurs early in S-phase
In order to determine when, during the cell cycle,
CDC7/DBF4 interacts with TOP2A, we immunoprecipi-
tated TOP2A fromT-REx-DBF4 cells that had been treated
with mimosine or nocodazole. Mimosine blocks S-phase
entry through activation of ATM checkpoint signaling and
inhibition of the chromatin binding of key replication pro-
teins (53,54), while nocodazole, a microtubule depolymeriz-
ing agent, prevents mitotic progression through activation
of the spindle assembly checkpoint (Figure 3A) (55). We
found that the amount of endogenous CDC7 and tagged
DBF4 co-immunoprecipitated was higher in cells arrested
with mimosine, and reduced in nocodazole-treated cells
(Figure 3B). We noted that DBF4 migrates slower in SDS-
PAGE when cells were treated with mimosine, possibly due
to phosphorylation by either ATM or ATR (56).
To examine if the interaction between TOP2A and
CDC7/DBF4 is modulated during progression through S-
phase, T-REx-DBF4 cells were released from mimosine ar-
rest and samples collected at 3-h intervals. DNA content
analysis and EdU incorporation assay indicated that T-REx
cells progressed slowly into S-phase (Figure 3C) in amanner
that was independent from DBF4 overexpression (Supple-
mentary Figure S3). After IP-Western, we found that the in-
teraction of TOP2A with CDC7 and tagged DBF4 was sig-
nificantly higher in mimosine-trapped cells compared to a
control-treated asynchronous population (Figure 3D, lanes
2 and 3), that it peaked between 3 and 9 h after release, when
most cells were in early to mid S-phase (Figure 3C and D
lanes 4–6) and decreased significantly by 12 h when most
cells were in mid and late S-phase (Figure 3C and D, lane
7).
CDC7 inhibition reduces TOP2A phosphorylation levels and
TOP2A-DDK protein-protein interaction in vivo
Since TOP2A interacts with DDK during S-phase and it is
a good in vitro substrate of the kinase, we asked if TOP2A
is phosphorylated in a CDC7-dependent manner in a cellu-
lar context. For this purpose, T-REx-EV cells were treated
for 3 h with XL413, a specific CDC7 inhibitor (49,50),
or mock treated. Under these conditions, phosphoryla-
tion of MCM2 at Ser40/41, a reliable marker of cellular
CDC7 activity (7), is strongly reduced (Figure 4A). When
TOP2A was analyzed by western blot on standard SDS-
PAGE we did not observe differences in the mobility of
the protein in the two samples. Thus, to facilitate separa-
tion of differentially phosphorylated TOP2A species, Phos-
tag acrylamide, which slows the migration of phosphory-
lated proteins relative to their unphosphorylated or less-
phosphorylated forms (57), was added to the SDS-PAGE
gels. In mock-treated cells, the TOP2A band becomes less
distinct in the presence of the Phos-tag reagent, with slight
smearing observed beneath the main band. Upon treat-
ment with the CDC7 inhibitor, a second, faster migrating
formwas detected (Figure 4A), suggesting that at least some
TOP2A phosphorylation could be attributed to CDC7 ki-
nase.
During the course of these experiments, we observed that
the electrophoretic mobility of DFB4-Strep protein was
greatly altered by the CDC7 inhibitor (Figure 4B), indicat-
ing that DBF4 itself is phosphorylated by CDC7, consistent
with the identification of thio-phosphorylated DBF4 pep-
tides in our initial experiments (Figure 1C) as well as with
increased mobility after phosphatase treatment of the ex-
tract (Figure 4C). Significantly, treatment with XL413 also
caused an evident and sudden drop inDBF4 levels that were
only marginally rescued by the co-treatment with the pro-
teasome inhibitorMG132; yet, XL413 did not affect CDC7
levels (Figure 4B and D).
We then investigated if the TOP2A-DDK interaction was
also affected by the compound. To this end, cells were
treated with either DMSO or XL413 for 3 h, and TOP2A
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Figure 4. CDC7 inhibitors affect the phosphorylation levels of cellular
TOP2A and its interaction with the kinase. (A) T-REx-EV cells were
treated with 10 MXL413 or DMSO for 3 h, and cell extracts were sepa-
rated on a 5% SDS-PAGE supplemented with 5 M Phos-tag acrylamide
or on a standard 6% SDS-PAGE. (B) T-REx-DBF4 cells were treated with
DMSO or XL413 for the indicated times in the presence of absence of pro-
teasome inhibitor MG132. (C) Extracts prepared from T-REx-DBF4 cells
were incubated in phosphatase reaction buffer in the presence or absence
of -phosphatase. (D) T-REx-DBF4 cells were treated with mimosine for
12 h, then with 10 M XL413 or DMSO for a further 3 h and immuno-
precipitations were performed with anti-TOP2A antibody or control IgG.
Immunoprecipiations were perfomed from 1.5 mg of extract and 20 g of
the input material (1.33%) was loaded on the gel. In all cases proteins were
analyzed by western blotting; where indicated, low or high intensity scans
of the same blot are shown.
immunoprecipitation experiments were performed. Both
CDC7 and DBF4 were detected in the immunoprecipitated
material from the control-treated sample, but not in the
XL413-treated sample (Figure 4D, lanes 5 and 6). Alto-
gether these data show that inhibition of CDC7 kinase ac-
tivity has multiple consequences on the phosphorylation,
the levels, and the capability of CDC7/DBF4 to inter-
act with and phosphorylate relevant substrates, including
TOP2A.
DBF4 localises to centromeres throughout S-phase
Both CDC7 and DBF4 are known to be mostly nuclear
proteins (5,6,58), but their sub-nuclear localization has not
been well characterized, particularly in human cells due to
the lack of sensitive and specific immunological reagents.
We therefore examined the localization of tagged DBF4 by
immunofluorescence microscopy with an anti-Strep anti-
body. Firstly, we confirmed that full-length tagged DBF4 is
mostly confined to the nucleus, where it is largely diffused.
However, extraction of soluble proteins before fixation re-
Figure 5. DBF4 is localized at centromeres throughout S-phase. (A) U2OS
cells transiently expressing DBF4-FLAG-Strep were treated with 10 M
EdU for 15min prior to pre-extraction and fixation. EdU-containingDNA
is shown inmagenta, DBF4 in green, and centromeres (ACA) in red. Early,
mid or late S-phase cells were determined according to the pattern of EdU
incorporation.Areas indicated in boxes aremagnified next to the respective
images. Scale bar = 10 m. (B) U2OS cells were transfected with plasmid
expressing EGFP-DBF4 fusion protein and analysed by fluorescence mi-
croscopy. EGFP signal is in green andACAcentromeric staining in red. (C)
Chromatin immunoprecipitations (ChIP) were performed with anti-Strep
and anti-RNApol II (RPB1) antibodies from extracts of T-REx-EVandT-
REx-DBF4 cells. The amounts of the non-centromeric GAPDH promoter
and Chromosome 1 centromeric (Cent1) DNA recovered were determined
by qPCR relative to the input samples. Bars represent the Mean ± S.D. of
three technical replicates. Results are representative of three independent
experiments.
vealed the presence of multiple DBF4 foci. By perform-
ing co-localization experiments, we observed that DBF4
foci did not obviously overlap with sites of active DNA
replication, but co-stainingwith anti-centromere antibodies
(ACA) showed that DBF4 foci could always be detected at
centromeres (Figure 5A). DBF4 was present at centromeres
at all stages of S-phase, and, interestingly, this was not af-
fected by CDC7 kinase inhibition by XL413 (Supplemen-
tary Figure S4). Using the same DBF4 deletion mutants
previously described, we investigated the domains required
for its chromatin and centromeric localization. Expression
plasmids for the DBF4 fragments were transfected into
U2OS cells, and their localization detected by IF as before.
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Figure 6. TOP2A is recruited to, and is active at centromeres in mid to late S-phase. (A) U2OS cells were treated with 10 MEdU and 50 g/ml ICRF-187
for 15 min prior to pre-extraction, fixation and immunofluorecence microscopy analysis. On top the pattern of EdU incorporation is shown in grey while
on the bottom TOP2A is shown in green and centromeres (ACA) in red. Areas indicated in boxes are magnified below the respective images. Scale bar= 10
m. (B) Cells in early and late S-phase were randomly selected and the proportion of centromeres co-incident with TOP2A foci were manually quantified.
Each point on the graph represents data from 1 cell. Bars represent the mean ± S.D. ****P < 0.0001, Student’s t-test.
We found that while the N-terminal domain alone was suf-
ficient for chromatin binding, all three NMC domains are
required for centromeric recruitment (Supplementary Fig-
ure S5).
To confirmDBF4 localization at centromeres, we first ex-
pressed a EGFP-DBF4 fusion protein in U2OS cells; again,
we observed that this protein was largely diffused in the
nucleus but also accumulated in foci that, to great extent,
overlapped with ACA foci (Figure 5B). Secondly, we used
chromatin immunoprecipitation (ChIP) technique. qPCR
primers were selected to amplify a centromere-specific tar-
get sequence on Chromosome 1 (Cent1) (47) and a non-
centromeric sequence corresponding to the GAPDH pro-
moter close to the transcription start site. We performed
ChIP using a long spacer cross-linker and anti-Strep and
anti-RNApolymerase II (RPB1) antibodies. As the baseline
control for background antibody binding, ChIP from T-
REx-EV cells was performed alongside T-REx-DBF4 cells.
By qPCR analysis, the abundance of each target locus re-
covered was calculated relative to the 2% input sample (Fig-
ure 5C). As the positive control for the ChIP protocol, oc-
cupancy of RNA polymerase II at the GAPDH promoter
was used. ChIP with the anti-Strep antibody showed in-
creased occupancy of tagged DBF4 at centromeric com-
pared to a non-centromeric locus, again supporting the idea
that DBF4 accumulates at centromeres.
TOP2A recruitment at centromeres occurs throughout S-
phase
We then investigated if CDC7/DBF4 affects either the ac-
tivity or subcellular localization of TOP2A. To detect cat-
alytically active TOP2A, we used the Differential Reten-
tion of Topoisomerase (DRT) assay (37). Briefly, asyn-
chronously growing U2OS cells were treated with the
TOP2A catalytic inhibitor ICRF-187/dexrazoxane, which
prevents the release of catalytically-committed TOP2A
from DNA (34,35). Soluble proteins, including TOP2A
molecules not involved in strand passage activity dur-
ing the time of treatment, are then salt-and detergent-
extracted prior to formaldehyde fixing and immunofluores-
cence microscopy; for reference, centromeres were detected
using anti-centromere antibodies. As previously reported,
TOP2A was detected along the chromosome axes and con-
centrated at centromeres of mitotic chromosomes (Supple-
mentary Figure S6 and (37,59)). Interestingly, we also ob-
served centromeric localization in a number of interphase
cells. In contrast to mitotic cells, however, not all interphase
centromeres co-localized with TOP2A, and the proportion
of TOP2A positive centromeres differed between cells. To
further stratify the interphase cells within the cell cycle, a
brief treatment with EdU was introduced, and cells were
determined to be in early, mid, or late S-phase according to
the pattern of EdU incorporation observed (60). The pro-
portion of TOP2Apositive centromeres per cell appeared to
correlate with S-phase progression, low in early S-phase and
increasing in late S-phase (Figure 6A). To quantify this re-
sult, the total number of discernible centromeres in a single
optical section of a randomly selected cell was counted, and
the percentage of centromeres that were also co-stainedwith
TOP2A was determined (Figure 6B). A significantly higher
proportion of TOP2A positive centromeres was found in
late S-phase cells compared to early S-phase. Thus, we con-
clude that TOP2A recruitment to centromeres is a gradual
process that occurs throughout S-phase.
CDC7/DBF4 limits TOP2A recruitment in early S-phase
Since both CDC7/DBF4 and TOP2A are localized at
centromeres in S-phase, we postulated that CDC7/DBF4
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Figure 7. CDC7/DBF4 inhibition increases the recruitment of TOP2A to centromeres. U2OS cells were transfected with siRNA against CDC7 and/or
DBF4 for 48 h. Cell extrects were then prepared and analysed by western blotting (A) or cells were treated with 10 M EdU and 50 g/ml ICRF-187
for 15 min prior to pre-extraction, fixation and immunofluorecence microscopy analysis (B). Representative images of early S-phase cells are shown. (C)
Quantification was performed as in Figure 6. ***P < 0.001, Student’s t-test. Scale bar = 10 m. (D) U2OS cells were challenged with 10 M XL413, 10
M PHA767491 or with DMSO as control. 15 min before harvesting cells were also treated with 10 M EdU and 50 g/ml ICRF-187 and analysed as
above. *P < 0.05, Student’s t-test.
might regulate the centromeric recruitment or activity of
TOP2A at these locations. Using the DRT assay we there-
fore examined the localization of TOP2Aafter 48 h of trans-
fection with siRNA targeting CDC7 and/or DBF4. While
endogenous CDC7 can be easily detected by western blot-
ting, the detection of endogenous DBF4 in these cells was
problematic, therefore in these experiments, the biological
readout of the efficiency of siRNA-mediated depletion of
DDK subunits was also determined indirectly through a
reduction in MCM2 phosphorylation, either as a mobility
shift or at a specific CDC7–dependent phosphorylation site
Ser40/41 (Figure 7A). After 48 h of transfection of siRNAs
a large proportion of the cells were still actively prolifer-
ating despite low DDK activity, and importantly, in those
cells that were actively undergoing DNA synthesis, we ob-
served an increased proportion of centromeres marked with
active TOP2A. This was particularly striking in cells with
an early S-phase replication pattern (Figure 7B), where the
number of TOP2A positive centromeres is typically low in
unperturbed conditions (Figure 6). Quantification of ran-
domly selected early S-phase cells confirmed a large increase
in TOP2A positive centromeres caused by CDC7 kinase de-
pletion (Figure 7C). Notably, combined depletion of CDC7
and DBF4 did not result in an additive effect on TOP2A
centromeric recruitment. Similarly to siRNA depletion of
the protein, a 3-h treatment with CDC7 inhibitors, XL413
or PHA767491, also caused increased localization of ac-
tive TOP2A at centromeres in early S-phase cells (Figure
7D). These data are consistent with either TOP2A activ-
ity at centromeres being directly regulated through TOP2A
phosphorylation by CDC7/DBF4, or indirectly through a
different mechanism.
In order to discriminate between these alternative mod-
els, we expressed either FLAG- tagged TOP2A WT, a
phosphorylation-deficient TOP2A protein carrying alanine
substitutions in the two serines that were identified as
CDC7 phospho-sites in vitro, namely S1213A/S1525A,
or the corresponding potential phospho-mimetic protein
S1213D/S1525D. All these proteins were catalytically ac-
tive in the cells as they could be trapped on chromatin
with ICRF187 although we noticed their expression level
was reproducibly different, with S1213A/S1525A protein
accumulating to higher levels (Figure 8A). This may be
due to protein or mRNA stabilization caused by the single
S1525A substitution, as an independent report showed that
a S1525A TOP2A was consistently expressed at a higher
level than the WT protein (43). When we analysed cen-
tromeric occupancy in early S-phase cells, we found that
the ectopically expressed FLAG-tagged TOP2A WT, just
like endogenous TOP2A or the S1213D/S1525D TOP2A,
was detected at low frequency at centromeres, while, in con-
trast, the phospho-deficient S1213A/S1525A protein dis-
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Figure 8. Phosphorylation at Ser1213 and S1525 controls the timing of TOP2A recruitment at centromeres. U2OS cells were tranfected with constructs
expressing eitherWT, S1213A/S1525A or S1213D/S1525DFLAG-tagged TOP2A. After 48 h, cell extracts were prepared and analysed by western blotting
(A) or cells were treated with 10 MEdU and 50 g/ml ICRF-187 for 15 min prior to pre-extraction, fixation and immunofluorecence microscopy analysis
(B). Representative images of early S-phase cells are shown. (C) Quantification was performed as in Figures 6 and 7. ***P < 0.001, Student’s t-test. Scale
bar = 10 m.
played increased occupancy, to a level similar to what was
observed with endogenous TOP2A when CDC7 kinase was
depleted (Figure 8B and C). Since the amount of TOP2A
active at centromeres is a very small fraction of the total
TOP2A pool in each cell analysed, it is unlikely that cen-
tromeric recruitment is driven solely bymass action equilib-
rium suggesting instead that phosphorylation at these sites
regulates TOP2A centromeric function.
DISCUSSION
In this work, we have used a chemical genetics approach to
identify potential substrates of CDC7 kinase from nuclear
extracts. During this process we have validated the idea that
two methionines, M118 and M134, can act as gatekeeper
residues, and their substitution with a smaller amino acid
such as alanine, either in combination or on their own, al-
lows the bulky ATP analogue N6-(benzyl)ATP to bind and
to be used as a cofactor instead of ATP for both auto- and
trans-phosphorylation of proteins. Our attempts to label
and capture CDC7 substrates from nuclear extracts have
led to the identification of TOP2A as a main substrate and
to the identification of S1213 and S1525 as CDC7 in vitro
phospho-sites. However, the list of potential substrates is
not exhaustive, as we did not retrieve known CDC7 sub-
strates, such as theMCMcomplex orCLASPIN. This could
be due to a combination of technical reasons, including the
use of an engineered kinase that lacks portions of DBF4
sequence that could be relevant to promote substrate recog-
nition. We also mapped seven sites of autophosphorylation
on the CDC7 catalytic subunit, and three on DBF4. All the
mapped CDC7 sites reside in the large insert domain, for
which structural information is lacking. This insert domain
interrupts the contiguity of the canonical kinase domain
structure, a feature which is peculiar to CDC7 and has been
shown to mediate protein-protein interactions (61). Inter-
estingly, several of these sites were also previously identified
in large phosphoproteomics studies and have been anno-
tated in the PhosphositePlus database (62), suggesting that
CDC7 auto-phosphorylation can occur in vivo.
We have demonstrated that DBF4 can be detected at
centromeres. To our knowledge, this is the first evidence
that DBF4 is recruited to centromeres in human cells. We
found that dual crosslinking with formaldehyde and ethy-
lene glycol bis (succinimidyl succinate) (EGS)was necessary
to immunoprecipitate DBF4-associated chromatin. EGS is
a protein-protein cross-linking agent with a long spacer arm
that, in combination with formaldehyde, stabilises proteins
that are not directly bound to DNA (63). This suggests
that CDC7/DBF4 is instead recruited through other pro-
tein factor(s). We have also found that the N-terminal 1–
209 residues of DBF4 are sufficient for chromatin bind-
ing. This region remains poorly characterized, but it con-
tains a BRCT domain proposed to be involved in protein–
protein interactions. Interestingly, the equivalent domain of
DBF4 in budding yeast, Saccharomyces cerevisiae, has been
shown to be required for interaction with several replica-
tion and checkpoint proteins, including ORC, RAD53 and
RIF1 (64–66). The mechanism regulating CDC7/DBF4
centromeric recruitment, however, is likely to be distinct, as
the DBF4 M and C domains, in an addition to the N do-
main, are also required for this.
It was recently reported that in S. cerevisiae,
CDC7/DBF4 is recruited to kinetochores where it
promotes the replication of centromeric regions early in
S-phase through the recruitment of the essential replication
proteins SLD3 and SLD7 (Treslin/TICRR and MTBP
in humans) to pericentromeric origins (67). Differently
from budding yeast, however, human centromeric DNA
is replicated asynchronously between mid to late S-phase
(68,69) while here DBF4 was detected at all centromeres
from early S-phase, inconsistent with normal centromeric
replication timing. As our experiments rely on the over-
expression of DBF4, future studies would be necessary to
verify if the overexpression of DBF4 is sufficient to alter
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centromeric DNA replication timing. In the same study,
the authors also reported that centromeric ScCDC7/DBF4
independently recruits the SCC2–SCC4 cohesin loading
complex for the establishment of robust pericentromeric
sister chromatid cohesion (67). X. laevis CDC7/DBF4B,
which is the predominant CDC7 kinase complex in egg
extracts, also physically interacts with SCC2-SCC4 and is
required for its chromatin binding (70). Thus, it is plausible
that human CDC7/DBF4 may also be involved in the es-
tablishment of pericentromeric sister chromatid cohesion,
and it would be interesting to verify if the homologous
complex in humans, NIPBL-MAU2, is also regulated by
CDC7 kinase in a similar manner.
CDC7/DBF4 interacts with and phosphorylates TOP2A
in vitro. The interaction likely occurs on chromatin, re-
quires a region of DBF4 that is sufficient for CDC7 acti-
vation, is further stabilized by the C-terminal tail of DBF4
and, interestingly, it is abolished by a very specific CDC7
ATP-competitive inhibitor XL413. At present, it is not fully
clear if this interaction is solely mediated by CDC7 or if it
is phosphorylation-dependent, as CDC7 kinase inhibition
has dramatic effects on both CDC7 and DBF4 phosphory-
lation levels as well as causing a rapid drop in DBF4 lev-
els. TOP2A is a highly modified protein with many residues
phosphorylated in its C-terminus (62) and several kinases
have been implicated in its regulation during the cell cy-
cle including CK2 and proline directed kinases (71) which
have mainly been studied using in vitro assays. As the treat-
ment with XL413 causes a reduction in the overall levels
of TOP2A phosphorylation, we propose that CDC7 is also
directly involved in the regulation in vivo. Future studies,
involving the development and thorough validation of mul-
tiple anti-phosphopeptide antibodies will be important to
determine the contribution of CDC7 and other kinases to
TOP2A phosphorylation at different sites.
Our work has also revealed that active TOP2A can be
detected at an increasing number of centromeres as cell
progress through S-phase. We observed that TOP2A activ-
ity at centromeric regions does not always overlap with on-
going DNA synthesis at these sites, and that the timing of
TOP2A centromeric recruitment is advanced by CDC7 de-
pletion. Similarly, the timing of centromeric recruitment of
a phosphorylation-deficient TOP2A at two key serines, pu-
tative CDC7 target sites S1213 and S1525, is advanced.
Based on these results, we propose that phosphorylation
of TOP2A by CDC7/DBF4 in early S-phase prevents its
localization and/or activity at centromeres, and inhibition
of TOP2A function could be relevant to prevent premature
separation of centromeric DNA.
CDC7 regulation of TOP2A at centromeres may have im-
portant significance with respect to centromeric replication
and cohesion, and could also explain the increased sensitiv-
ity to TOP2 poisons in cells lacking CDC7 activity.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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